Skip to content

LandBridge

US · LB #1859 by market cap Listed 2024
70.39 -1.04 -1.46%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Recent news

  • Rating change
    Piper Sandler Maintains LandBridge(LB.US) With Hold Rating, Maintains Target Price $88
    Market Newswire · 2026/10/12
  • Piper Sandler Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $78
    Market Newswire · 2026/11/6
  • Rating change
    LB Pharmaceuticals, Inc. (LBRX) Gets a Buy From Guggenheim
    TipRanks · 2026/10/13
  • Company notice
    Lb Semicon: Report on Status of Specific Securities, Etc. Owned by Executives and Major Shareholders
    OPENDART · 2026/8/19
  • Rating change
    Raymond James Maintains LandBridge(LB.US) With Buy Rating, Raises Target Price to $91
    Market Newswire · 2026/10/19
  • BMO Capital Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $54
    Market Newswire · 2026/11/6
  • Rating change
    CCORF Initiates LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $65
    Market Newswire · 2026/10/9
  • Rating change
    Barclays Maintains LandBridge(LB.US) With Hold Rating, Maintains Target Price $75
    Market Newswire · 2026/11/6
  • Guggenheim Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $80
    Market Newswire · 2026/11/13
  • Company notice
    Nippecraft: Financial Statements and Related Announcement-Notification of Results Release
    SGX · 2026/7/9
  • H.C. Wainwright Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2026/11/9
  • Company notice
    Nippecraft: Financial Statements and Related Announcement-Half Yearly Results
    SGX · 2026/8/12
  • Company notice
    4: LB Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-10% Owner Deep Track Biotechnology Master Fund, Ltd.
    SEC · 2026/8/4
  • Company notice
    Lb Semicon: Report on Significant Holdings of Stocks, Etc. (General)
    OPENDART · 2026/9/29
  • Rating change
    A Quick Look at Today's Ratings for LB Pharmaceuticals(LBRX.US), With a Forecast Between $54 to $80
    Market Newswire · 2026/10/28
  • Rating change
    Goldman Sachs Maintains LandBridge(LB.US) With Buy Rating, Raises Target Price to $97
    Market Newswire · 2026/10/12
  • Rating change
    Analysts Offer Insights on NA Companies: SpaceX (SPCX), Six Flags Entertainment Corporation (FUN) and LB Pharmaceuticals, Inc. (LBRX)
    TipRanks · 2026/10/21
  • Rating change
    Stifel Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $53
    Market Newswire · 2026/10/21
  • Rating change
    LB Pharmaceuticals, Inc. (LBRX) Gets a Buy From H.C. Wainwright
    TipRanks · 2026/10/12
  • CCORF Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $65
    Market Newswire · 2026/11/7
  • Rating change
    Piper Sandler Maintains LandBridge(LB.US) With Hold Rating, Raises Target Price to $88
    Market Newswire · 2026/9/1
  • Rating change
    Guggenheim Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $80
    Market Newswire · 2026/10/13
  • Rating change
    Needham Initiates LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $68
    Market Newswire · 2026/10/2
  • Piper Sandler Maintains LB Pharmaceuticals(LBRX.US) With Buy Rating, Maintains Target Price $78
    Market Newswire · 2026/10/29
  • Rating change
    Citi Initiates LandBridge(LB.US) With Hold Rating, Announces Target Price $86
    Market Newswire · 2026/8/26

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:01:25 · For reference only, not investment advice and not tailored to your situation.

LandBridge discussion 0 comments

Add a comment